I 
118TH CONGRESS 
2D SESSION 
H. R. 9886 
To require the Administrator of the Drug Enforcement Administration to 
temporarily exempt buprenorphine from the Suspicious Orders Report 
System for the remainder of the opioid public health emergency. 
IN THE HOUSE OF REPRESENTATIVES 
SEPTEMBER 27, 2024 
Mr. TONKO introduced the following bill; which was referred to the Committee 
on Energy and Commerce, and in addition to the Committee on the Judi-
ciary, for a period to be subsequently determined by the Speaker, in each 
case for consideration of such provisions as fall within the jurisdiction of 
the committee concerned 
A BILL 
To require the Administrator of the Drug Enforcement Ad-
ministration to temporarily exempt buprenorphine from 
the Suspicious Orders Report System for the remainder 
of the opioid public health emergency. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Broadening Utilization 
of Proven and Effective Treatment for Recovery Act’’ or 
the ‘‘BUPE for Recovery Act’’. 
VerDate Sep 11 2014 
19:09 Oct 17, 2024
Jkt 059200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H9886.IH
H9886
ssavage on LAPJG3WLY3PROD with BILLS
SEC. 2. REMOVAL OF BUPRENORPHINE PRODUCTS FROM 
SORS 
DURING 
OPIOID 
PUBLIC 
HEALTH 
EMERGENCY. 
(a) TEMPORARY EXEMPTION.—The Administrator of 
the Drug Enforcement Administration shall temporarily 
exempt any buprenorphine product approved for the treat-
ment of opioid use disorder from the Suspicious Orders 
Report System established under 312 of the Controlled 
Substances Act (21 U.S.C. 832), including subsection 
(a)(3) of that section, until that date that is 270 days 
after the date on which the public health emergency with 
respect to opioids declared by the Secretary of Health and 
Human Services pursuant to section 319 of the Public 
Health Service Act (42 U.S.C. 247d) on October 26, 2017, 
expires. 
(b) REPORT.—Not later than 90 days after the date 
of the expiration of the public health emergency described 
in subsection (a), the Department of Justice and the De-
partment of Health and Human Services shall— 
(1) conduct a comprehensive report that indi-
cates if the temporary exemption under subsection 
(a) resulted in increased access to buprenorphine 
treatment for patients experiencing opioid use dis-
order; and 
(2) make a recommendation to the White 
House and Congress about whether buprenorphine 
VerDate Sep 11 2014 
19:09 Oct 17, 2024
Jkt 059200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H9886.IH
H9886
ssavage on LAPJG3WLY3PROD with BILLS
should remain in the Suspicious Orders Report Sys-
tem and be subject to related reporting requirements 
after the expiration of the public health emergency 
described in subsection (a). 
(c) SENSE OF CONGRESS.—It is the sense of Con-
gress that Congress is concerned by reports of patients 
not being able to fill buprenorphine prescriptions for the 
treatment of opioid use disorder at pharmacies. Reports 
indicate that pharmacies are unable or unwilling to stock 
sufficient buprenorphine products, in part because of the 
Suspicious Orders Report System and related reporting 
requirements. A temporary exemption of buprenorphine 
products approved for the treatment of opioid use disorder 
from Suspicious Order Report System requirements would 
allow the Federal Government to collect relevant data and 
assess whether a permanent exemption should be estab-
lished. 
Æ 
VerDate Sep 11 2014 
19:09 Oct 17, 2024
Jkt 059200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6301
E:\BILLS\H9886.IH
H9886
ssavage on LAPJG3WLY3PROD with BILLS